Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis : mechanisms and clinical implications.
Cardiovascular diseases are the leading cause of morbidity and mortality in the US. Proper management and/or prevention of atherosclerosis and hypertension, two complex and chronic disorders, would significantly reduce the risk for cardiovascular events such as myocardial infarction and stroke, but this requires an understanding of the mechanisms underlying their development and progression. Whereas a great deal has been learned and applied toward the management of these disorders, especially hypertension, morbidity and mortality remains unacceptably high, most likely because there are disease-causing mechanisms that have yet to be fully recognized. Understanding these disease mechanisms is necessary so that novel management strategies can be developed. One of these novel mechanisms centers on peroxisome proliferator-activated receptor (PPAR)-gamma. PPAR-gamma is a member of the nuclear receptor superfamily of ligand-activated transcription factors known to play a role in glucose homeostasis and adipocyte differentiation and, more recently, has been shown to have anti-inflammatory, antiatherogenic, and antihypertensive effects. Thiazolidinediones, a class of drugs used in the treatment of type 2 diabetes mellitus, are high-affinity ligands for PPAR-gamma. In this review, the anti-inflammatory, anti-atherosclerotic, and anti-hypertensive mechanisms by which PPAR-gamma and its agonists are thought to exert protective effects on the cardiovascular system are discussed. Ongoing clinical trials using PPAR-gamma activators for the management of cardiovascular diseases, especially in patients with type 2 diabetes mellitus, are summarized.
Halabi
Carmen M
CM
Medical Scientist Training Program, University of Iowa, Iowa City, Iowa 52242, USA.
Sigmund
Curt D
CD
D000476:Alkanesulfonates / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D002986:Clinical Trials as Topic; D002995:Clofibric Acid / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D023421:Models, Animal; D047495:PPAR gamma / Q000819:agonists* / Q000235:genetics / Q000378:metabolism; D010666:Phenylpropionates / Q000494:pharmacology / Q000627:therapeutic use*; D045162:Thiazolidinediones / Q000494:pharmacology / Q000627:therapeutic use*
D000476:Alkanesulfonates; D047495:PPAR gamma; D010666:Phenylpropionates; D045162:Thiazolidinediones; D002995:Clofibric Acid; C501413:tesaglitazar